Key barriers in adhering to anticoagulation guidelines included uncertainty about its choice, established practices, and the ...

AstraZeneca PLC (LON:AZN), a leading global biopharmaceutical company with a market capitalization of $216.74 billion, has been making significant strides in the pharmaceutical industry, particularly ...

The launch of My Green Lab Certification 2.0 introduces enhanced tools and resources to drive measurable impact in ...

The latest trading day saw Astrazeneca (AZN) settling at $70.25, representing a +0.95% change from its previous close.

The FDA clearance aids AstraZeneca and Daiichi Sankyo’s plan to position ADCs like Enhertu ahead of chemotherapy in a variety ...

UBS analyst Matthew Weston maintained a Hold rating on AstraZeneca (AZN – Research Report) today and set a price target of p11,500.00. The ...

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

How does the US stock market stack up against its UK counterpart and how does their recent performance compare?

AstraZeneca PLC closed 16.10% below its 52-week high of £133.88, which the company reached on September 3rd.

Nancy Ghattas, VP, US franchise head, imunno-oncology, gastrointestinal tumors, AstraZeneca, discusses the promising results ...

AstraZeneca AZN will report its fourth-quarter and full-year 2024 earnings on Feb. 6, before market open. The Zacks Consensus ...

Lantheus is acquiring radiopharmaceutical CDMO Evergreen Theragnostics in a deal worth up to $1 billion, expanding its manufacturing capabilities and drug pipeline. The acquisition includes Octevy, a ...